{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T14:26:29Z","timestamp":1792765589932,"version":"4.5.0"},"reference-count":38,"publisher":"American Association for the Advancement of Science (AAAS)","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T00:00:00Z","timestamp":1626393600000},"content-version":"vor","delay-in-days":196,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003827","name":"NKFIH","doi-asserted-by":"publisher","award":["2018-1.3.1-VKE-2018-00032"],"award-info":[{"award-number":["2018-1.3.1-VKE-2018-00032"]}],"id":[{"id":"10.13039\/501100003827","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003827","name":"NKFIH","doi-asserted-by":"publisher","award":["2018-2.1.17-TET-KR-00001"],"award-info":[{"award-number":["2018-2.1.17-TET-KR-00001"]}],"id":[{"id":"10.13039\/501100003827","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003827","name":"NKFIH","doi-asserted-by":"publisher","award":["FIEK_16-1-2016-0005"],"award-info":[{"award-number":["FIEK_16-1-2016-0005"]}],"id":[{"id":"10.13039\/501100003827","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015498","name":"Innov\u00e1ci\u00f3s \u00e9s Technol\u00f3giai Miniszt\u00e9rium","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015498","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002332","name":"Semmelweis Egyetem","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002332","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["csbj.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Comput Struct Biotechnol J"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Extensive research is directed to uncover new biomarkers capable to stratify breast cancer patients into clinically relevant cohorts. However, the overall performance ranking of such marker candidates compared to other genes is virtually absent. Here, we present the ranking of all survival related genes in chemotherapy treated basal and estrogen positive\/HER2 negative breast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched the GEO repository to uncover transcriptomic datasets with available follow-up and clinical data. After quality control and normalization, samples entered an integrated database. Molecular subtypes were designated using gene expression data. Relapse-free survival analysis was performed using Cox proportional hazards regression. False discovery rate was computed to combat multiple hypothesis testing. Kaplan-Meier plots were drawn to visualize the best performing genes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The entire database includes 7,830 unique samples from 55 independent datasets. Of those with available relapse-free survival time, 3,382 samples were estrogen receptor-positive and 696 were basal. In chemotherapy treated ER positive\/ERBB2 negative patients the significant prognostic biomarker genes achieved hazard rates between 1.76 and 3.33 with a p value below 5.8E\u221204. The significant prognostic genes in adjuvant chemotherapy treated basal breast cancer samples reached hazard rates between 1.88 and 3.61 with a p value below 7.2E\u221204. Our integrated platform was extended enabling the validation of future biomarker candidates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A reference ranking for all genes in two chemotherapy treated breast cancer cohorts is presented. The results help to neglect those with unlikely clinical significance and to focus future research on the most promising candidates.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.csbj.2021.07.014","type":"journal-article","created":{"date-parts":[[2021,7,18]],"date-time":"2021-07-18T03:03:29Z","timestamp":1626577409000},"page":"4101-4109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":879,"title":["Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer"],"prefix":"10.34133","volume":"19","author":[{"given":"Bal\u00e1zs","family":"Gy\u0151rffy","sequence":"first","affiliation":[{"name":"Semmelweis University Dept. of Bioinformatics, T\u0171zolt\u00f3 utca 7-9., 1094 Budapest, Hungary"},{"name":"TTK Momentum Cancer Biomarker Research Group, Institute of Enzymology, Magyar Tud\u00f3sok k\u00f6r\u00fatja 2., 1117 Budapest, Hungary"},{"name":"Semmelweis University 2nd Dept. of Pediatrics, T\u0171zolt\u00f3 utca 7-9., 1094 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"221","published-online":{"date-parts":[[2021,7,28]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"crossref","unstructured":"Siegel RL Miller KD Jemal A. Cancer statistics 2020. CA A Cancer J Clin 2020;70:7\u201330. https:\/\/doi.org\/10.3322\/caac.21590.","DOI":"10.3322\/caac.21590"},{"key":"e_1_3_5_3_2","volume-title":"Diagnostic pathology: breast","author":"Lester S.","year":"2016","unstructured":"Lester S. and Hicks D.: Diagnostic pathology: breast. : Elsevier 2016."},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.19323"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052306"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1001389"},{"key":"e_1_3_5_7_2","doi-asserted-by":"crossref","unstructured":"Howlader N Altekruse SF Li CI Chen VW Clarke CA Ries LAG et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. JNCI: J Natl Cancer Inst 2014;106. https:\/\/doi.org\/10.1093\/jnci\/dju055.","DOI":"10.1093\/jnci\/dju055"},{"key":"e_1_3_5_8_2","doi-asserted-by":"crossref","unstructured":"Pernas S Tolaney SM Winer EP Goel S. CDK4\/6 inhibition in breast cancer: current practice and future directions. Ther Adv Med Oncol 2018;10:175883591878645. https:\/\/doi.org\/10.1177\/1758835918786451.","DOI":"10.1177\/1758835918786451"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706450"},{"key":"e_1_3_5_10_2","doi-asserted-by":"crossref","unstructured":"Godet I Gilkes DM. BRCA1 and BRCA2 mutations and treatment strategies for breast cancer. Integr Cancer Sci Ther 2017;4. https:\/\/doi.org\/10.15761\/ICST.1000228.","DOI":"10.15761\/ICST.1000228"},{"key":"e_1_3_5_11_2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13058-015-0514-2","article-title":"Multigene prognostic tests in breast cancer: past, present, future","volume":"17","author":"Gy\u0151rffy B.","year":"2015","unstructured":"Gy\u0151rffy B., Hatzis C., Sanft T., Hofstatter E., Aktas B. and Pusztai L.: Multigene prognostic tests in breast cancer: past, present, future. Breast Cancer Res 2015; 17: 11.","journal-title":"Breast Cancer Res"},{"key":"e_1_3_5_12_2","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/1097-0142(19810201)47:3<554::AID-CNCR2820470322>3.0.CO;2-W","article-title":"Estrogen receptor: a prognostic factor in breast cancer","volume":"47","author":"Samaan N.A.","year":"1981","unstructured":"Samaan N.A., Buzdar A.U., Aldinger K.A., Schultz P.N., Yang K.P., Romsdahl M.M. et al: Estrogen receptor: a prognostic factor in breast cancer. Cancer 1981; 47: 554.","journal-title":"Cancer"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.3798106"},{"key":"e_1_3_5_14_2","doi-asserted-by":"crossref","first-page":"e5645","DOI":"10.1371\/journal.pone.0005645","article-title":"Evaluation of microarray preprocessing algorithms based on concordance with RT-PCR in clinical samples","volume":"4","author":"Gyorffy B.","year":"2009","unstructured":"Gyorffy B., Molnar B., Lage H., Szallasi Z., Eklund A.C. and Creighton C.: Evaluation of microarray preprocessing algorithms based on concordance with RT-PCR in clinical samples. PLoS ONE 2009; 4: e5645.","journal-title":"PLoS ONE"},{"key":"e_1_3_5_15_2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/ijc.26364","article-title":"Meta-analysis of gene expression profiles associated with histological classification and survival in 829 ovarian cancer samples","volume":"131","author":"Fekete T.","year":"2012","unstructured":"Fekete T., R\u00e1s\u00f3 E., Pete I., Tegze B., Liko I., Munk\u00e1csy G. et al: Meta-analysis of gene expression profiles associated with histological classification and survival in 829 ovarian cancer samples. Int J Cancer 2012; 131: 95.","journal-title":"Int J Cancer"},{"key":"e_1_3_5_16_2","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","article-title":"Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013","volume":"24","author":"Goldhirsch A.","year":"2013","unstructured":"Goldhirsch A., Winer E.P., Coates A.S., Gelber R.D., Piccart-Gebhart M., Th\u00fcrlimann B. et al: Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013; 24: 2206.","journal-title":"Ann Oncol"},{"key":"e_1_3_5_17_2","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3390\/microarrays2030228","article-title":"Improving pathological assessment of breast cancer by employing array-based transcriptome analysis","volume":"2","author":"Mih\u00e1ly Z.","year":"2013","unstructured":"Mih\u00e1ly Z. and Gy\u0151rffy B.: Improving pathological assessment of breast cancer by employing array-based transcriptome analysis. Microarrays (Basel) 2013; 2: 228.","journal-title":"Microarrays (Basel)"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2008.211"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-009-0674-9"},{"key":"e_1_3_5_20_2","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1186\/1471-2105-12-474","article-title":"Jetset: selecting the optimal microarray probe set to represent a gene","volume":"12","author":"Li Q.","year":"2011","unstructured":"Li Q., Birkbak N.J., Gyorffy B., Szallasi Z. and Eklund A.C.: Jetset: selecting the optimal microarray probe set to represent a gene. BMC Bioinf 2011; 12: 474.","journal-title":"BMC Bioinf"},{"key":"e_1_3_5_21_2","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG) Peto R Davies C Godwin J Gray R Pan HC et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. Lancet 2012;379:432\u201344. https:\/\/doi.org\/10.1016\/S0140-6736(11)61625-5.","DOI":"10.1016\/S0140-6736(11)61625-5"},{"key":"e_1_3_5_22_2","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.mpsur.2017.12.002","article-title":"Principles of cancer treatment by chemotherapy","volume":"36","author":"Dickens E.","year":"2018","unstructured":"Dickens E. and Ahmed S.: Principles of cancer treatment by chemotherapy. Surgery (Oxford) 2018; 36: 134.","journal-title":"Surgery (Oxford)"},{"key":"e_1_3_5_23_2","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1200\/JCO.19.01866","article-title":"Patient-reported cognitive impairment among women with early breast cancer randomly assigned to endocrine therapy alone versus chemoendocrine therapy: results from TAILORx","volume":"38","author":"Wagner L.I.","year":"2020","unstructured":"Wagner L.I., Gray R.J., Sparano J.A., Whelan T.J., Garcia S.F., Yanez B. et al: Patient-reported cognitive impairment among women with early breast cancer randomly assigned to endocrine therapy alone versus chemoendocrine therapy: results from TAILORx. J Clin Oncol 2020; 38: 1875.","journal-title":"J Clin Oncol"},{"key":"e_1_3_5_24_2","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s10549-013-2622-y","article-title":"A meta-analysis of gene expression-based biomarkers predicting outcome after tamoxifen treatment in breast cancer","volume":"140","author":"Mih\u00e1ly Z.","year":"2013","unstructured":"Mih\u00e1ly Z., Kormos M., L\u00e1nczky A., Dank M., Budczies J., Sz\u00e1sz M.A. et al: A meta-analysis of gene expression-based biomarkers predicting outcome after tamoxifen treatment in breast cancer. Breast Cancer Res Treat 2013; 140: 219.","journal-title":"Breast Cancer Res Treat"},{"key":"e_1_3_5_25_2","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1904819","article-title":"Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer","volume":"380","author":"Sparano J.A.","year":"2019","unstructured":"Sparano J.A., Gray R.J., Ravdin P.M., Makower D.F., Pritchard K.I., Albain K.S. et al: Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. N Engl J Med 2019; 380: 2395.","journal-title":"N Engl J Med"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804710"},{"key":"e_1_3_5_27_2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s10549-020-05688-1","article-title":"EndoPredict\u00ae in early hormone receptor-positive, HER2-negative breast cancer","volume":"182","author":"Almstedt K.","year":"2020","unstructured":"Almstedt K., Mendoza S., Otto M., Battista M.J., Steetskamp J., Heimes A.S. et al: EndoPredict\u00ae in early hormone receptor-positive, HER2-negative breast cancer. Breast Cancer Res Treat 2020; 182: 137.","journal-title":"Breast Cancer Res Treat"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.e10-04-0335"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.2174\/156652412798376134"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.2419"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157368"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1315"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030804"},{"key":"e_1_3_5_34_2","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1093\/annonc\/mdv221","article-title":"Tailoring therapies\u2013improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015","volume":"26","author":"Coates A.S.","year":"2015","unstructured":"Coates A.S., Winer E.P., Goldhirsch A., Gelber R.D., Gnant M., Piccart-Gebhart M. et al: Tailoring therapies\u2013improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 2015; 26: 1533.","journal-title":"Ann Oncol"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2789"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25495"},{"key":"e_1_3_5_37_2","doi-asserted-by":"crossref","first-page":"e207213","DOI":"10.1001\/jamanetworkopen.2020.7213","article-title":"Association of independent prognostic factors and treatment modality with survival and recurrence outcomes in breast cancer","volume":"3","author":"Nguyen D.","year":"2020","unstructured":"Nguyen D., Yu J., Reinhold W.C. and Yang S.X.: Association of independent prognostic factors and treatment modality with survival and recurrence outcomes in breast cancer. JAMA Netw Open 2020; 3: e207213.","journal-title":"JAMA Netw Open"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605478"},{"key":"e_1_3_5_39_2","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1186\/1471-2407-14-837","article-title":"MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer","volume":"14","author":"P\u00e9nzv\u00e1lt\u00f3 Z.","year":"2014","unstructured":"P\u00e9nzv\u00e1lt\u00f3 Z., L\u00e1nczky A., L\u00e9n\u00e1rt J., Meggyesh\u00e1zi N., Kren\u00e1cs T., Szoboszlai N. et al: MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer. BMC Cancer 2014; 14: 837.","journal-title":"BMC Cancer"}],"container-title":["Computational and Structural Biotechnology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2001037021003044?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2001037021003044?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/spj.science.org\/doi\/pdf\/10.1016\/j.csbj.2021.07.014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T12:49:52Z","timestamp":1779022192000},"score":1,"resource":{"primary":{"URL":"https:\/\/spj.science.org\/doi\/10.1016\/j.csbj.2021.07.014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":38,"alternative-id":["10.1016\/j.csbj.2021.07.014"],"URL":"https:\/\/doi.org\/10.1016\/j.csbj.2021.07.014","relation":{},"ISSN":["2001-0370"],"issn-type":[{"value":"2001-0370","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer","name":"articletitle","label":"Article Title"},{"value":"Computational and Structural Biotechnology Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.csbj.2021.07.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author. Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology.","name":"copyright","label":"Copyright"}]}}